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ABSTRACT The herpes simplex virus DNA polymerase
consists oftwo subunits-a catalytic subunit and an accessory
subunit, UL42, that increases processivity. Mutations affect-
ing the extreme C terminus of the catalytic subunit specifi-
cally disrupt subunit interactions and ablate virus replication,
suggesting that new antiviral drugs could be rationally de-
signed to interfere with polymerase heterodimerization. To
aid design, we performed circular dichroism (CD) spectros-
copy and analytical ultracentrifugation studies, which re-
vealed that a 36-residue peptide corresponding to the C ter-
minus of the catalytic subunit folds into a monomeric struc-
ture with partial a-helical character. CD studies of shorter
peptides were consistent with a model where two separate
regions of a-helix interact to form a hairpin-like structure.
The 36-residue peptide and a shorter peptide corresponding to
the C-terminal 18 residues blocked UL42-dependent long-
chain DNA synthesis at concentrations that had no effect on
synthesis by the catalytic subunit alone or by calfthymus DNA
polymerase 6 and its processivity factor. These peptides,
therefore, represent a class of specific inhibitors of herpes
simplex virus DNA polymerase that act by blocking accessory-
subunit-dependent synthesis. These peptides or their struc-
tures may form the basis for the synthesis of clinically effective
drugs.
Herpes simplex virus (HSV) is a major human pathogen,
especially in immunocompromised patients such as those with
AIDS. Treatment has relied mainly on the drug acyclovir,
whose ultimate target is the virus-encoded DNA polymerase
(1). However, antiviral resistance is becoming a problem of
increasing clinical significance (2, 3), indicating the need for
alternative anti-HSV drugs. The HSV DNA polymerase still
remains an attractive drug target, as it is absolutely essential
for virus replication (1). Structurally, the enzyme consists of a
catalytic subunit (Pol) and a smaller subunit, UL42, that is not
necessary for polymerase activity per se but increases the
processivity of the enzyme (4, 5). Mutations that specifically
disrupt subunit interactions ablate virus replication, indicating
that these interactions are necessary for virus replication (6, 7).
This suggested the attractive possibility of rationally develop-
ing a class of polymerase inhibitors designed to interfere with
dimerization.
Residues crucial for the Pol-UL42 interaction and viral
replication lie at the extreme C terminus of Pol (6, 8, 9). Two
potential routes to antiviral drugs based on these residues are
(i) rational design starting from the structure of this region and
(ii) the development of peptidomimetic analogues of this re-
gion, which could be aided by structural information. Toward
these ends, we have conducted biophysical studies of peptides
corresponding to the extreme C terminus of Pol. Our results
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suggest that this region forms a discrete structure, which may
be amenable to high-resolution structural analysis. Further, we
have shown that certain such peptides specifically block the
functional consequences of UL42 binding and prevent pro-
cessive DNA synthesis, indicating the potential for peptido-
mimetic development.
MATERIALS AND METHODS
Materials. Peptides A and E were synthesized by a solid-
phase procedure using fluorenylmethoxycarbonyl chemistry
on a Milligen/Biosearch 9600 synthesizer. The peptides were
deblocked and cleaved from the resin by trifluoroacetic acid/
thioanisole/ethanedithiol/anisole (9:0.5:0.3:0.2, vol/vol) to
minimize oxidation of methionine and then precipitated and
washed with diethyl ether to remove impurities generated
during cleavage. Peptides C, D, and F were generously pro-
vided by Bio-Mega/Boehringer Ingelheim. Peptide B and cer-
tain lots of peptide E were purchased from Chiron. All pep-
tides were purified by HPLC and lyophilized for storage.
Working stocks were dissolved in dimethyl sulfoxide. Peptide
identities and concentrations were confirmed by amino acid
analysis carried out at the Brigham and Womens Hospital
Biopolymer Laboratory.
HSV Pol and UL42 were purified from insect cells infected
with the appropriate recombinant baculoviruses (6) and kindly
provided by Klaus Weisshart (D.M.C.'s laboratory). Partially
purified calf thymus DNA polymerase S and proliferating-cell
nuclear antigen (PCNA) were generously supplied by Bruce
Stillman (Cold Spring Harbor Laboratory).
CD Spectroscopy. Lyophilized peptides were resuspended in
10 mM KF and adjusted to pH 8 with KOH. Unless otherwise
specified, peptide concentrations were 100 ,uM, except for
peptide A, which was 40 ,uM. All spectra were recorded with
an Aviv 62DS spectropolarimeter at 0°C. Wavelength scans
were recorded at 1-nm intervals (10-sec averaging time), and
at least three scans were averaged.
Analytical Ultracentrifugation. Equilibrium sedimentation
experiments on peptide A were performed with a Beckman
XL-A analytical ultracentrifuge using double-sector cells with
charcoal-filled Epon centerpieces and sapphire windows. Ex-
periments were performed at 4°C and 25°C in 20 mM
Hepes/50 mM phosphate, pH 8.0, in H20 or 2H20 with an
initial peptide concentration of 30 ,uM. The distribution of the
peptide at various radii was assayed by absorbance at 230 nm.
Data were analyzed by nonlinear least-squares methods under
the control of a modified version of IGOR-PRO (WaveMetrics,
Abbreviations: HSV, herpes simplex virus; Pol, HSVDNA polymerase
catalytic subunit; PCNA, proliferating-cell nuclear antigen.
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Lake Oswego, OR) running on a Macintosh computer. Data
sets were collected at 18-24 hr, at rotor speeds of 50,000 and
60,000 rpm. Equilibrium was established by determining that
scans taken 4 hr apart were superimposible. To determine
whether the peptide behaved as a monomer or higher-order
assembly, an equation describing the macromolecular distri-
bution at sedimentation equilibrium for monodisperse systems
(single ideal species) was employed (10):
Cr = Co exp[M(1 - p)2(r2 - r02)/2RTJ + base, [1]
where Cr and co are the total concentrations of species at a
radial position, r, and at the meniscus (a reference position).
M and v- are the molecular weight and partial specific volume
of the macromolecule, p is the solvent density, w is the angular
velocity, ro is the reference radial position, R is the universal
gas constant, T is the absolute temperature, and base is a
baseline term corresponding to optical density from a non-
sedimenting material. Because the determination of v- for
peptide A by various predictive methods based on amino acid
composition gave very different answers, molecular mass and
v were measured simultaneously by the method of Edelstein
and Schachman (11) as extended by Eisenstein et al. (12), using
solvents of different densities (H20 and 2H20). The parame-
ters co, M, and base were determined by nonlinear least-
squares methods (13, 14). Data were analyzed in terms of
assembly models by fitting the data to sums of exponentials,
one for each additional species (14).
Polymerase Assays. Reaction mixtures (25 ,ul) containing 50
mM Tris-HCl (pH 7.6), 100 mM (NH4)2SO4, 3 mM MgCl2, 0.1
mM EDTA, 1 mM dithiothreitol, 4% (vol/vol) glycerol, 1 ,ug
of bovine serum albumin, 10% (vol/vol) dimethyl sulfoxide, 50
,uM dTTP, 0.25 gg of a poly(dA)*oligo(dT) template (15, 16),
25 fmol of HSV Pol, either no or 50 fmol of UL42, and the
indicated concentrations of a given peptide were incubated at
37°C for 30 min. In the experiment shown here, peptide A was
preincubated on ice for 15 min with UL42 in the reaction
mixture, and Pol was added last, whereas in other experiments,
there was no preincubation and UL42 was added last. Prein-
cubation increased the potency of peptide A about 10-fold but
had little or no effect on the potencies of other peptides (data
not shown). DNA synthesis was terminated by the addition of
3 volumes of 20mM EDTA/1% SDS containing salmon sperm
DNA (10 ,ug/ml), and the samples were ethanol precipitated
before electrophoresis in alkaline agarose gels. Newly synthe-
sised DNA was detected by autoradiography and quantified by
densitometry. For reactions containing Pol 8, (NH4)2SO4 was
omitted from the reaction buffer, and 0.5 ,ul of Pol 8 and 250
ng of PCNA were added in place of HSV Pol and UL42,
respectively.
RESULTS
A Peptide Corresponding to the C Terminus of Pol Has
a-Helical Character. Previous studies indicated that UL42
binds to the C terminus of Pol (17) and that within this region,
residues downstream of aa 1195 are crucial for interaction with
UL42 (6, 8, 9). Reasoning that proline residues at positions
1198 and 1199 (Fig. 1) might denote a turn between units of
secondary structure, we synthesized a peptide corresponding
to the last 36 residues (aa 1200-1235) of Pol (Fig. 1, peptide
A). A Robson-Garnier secondary-structure prediction algo-
rithm of this portion of Pol had predicted two regions of
a-helical structure interrupted by a poorly predicted region
centered on four closely spaced glycine residues (residues
1210-1217) for this region of Pol (Fig. 1), raising the possibility
of a hairpin-like helix-loop-helix structure (6). Consistent
with this prediction, the CD spectrum of peptide A in aqueous
solution (Fig. 2) exhibited double minima at 222 and =205 nm
and a maximum at 192 nm characteristic ofa-helices (19). The
1195 Helix I Loop Helix II 1235
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FIG. 1. Peptides corresponding to the C terminus of HSV-1 strain
KOS Pol. Residues 1195-1235 (18) (single-letter code) of Pol are
shown, with regions of predicted helix boxed. Peptides used in this
study are indicated by the bars, with acetylated (Ac-) and amidated
(-NH2) termini shown where appropriate.
intensity of the minimum at 222 nm indicated a helical content
of -22% (20). Even at 37°C, the value at 222 nm reflected
10-15% helicity (data not shown).
The C-Terminal Peptide Behaves as a Monomer. The de-
gree of helicity of peptide A did not vary substantially over the
concentration range 10-50 ,uM (data not shown) suggesting
that the peptide was monomeric in solution, but its limited
solubility in UV-transparent buffers precluded analysis over a
wider range of concentrations. Therefore we examined peptide
A by equilibrium analytical centrifugation to permit analysis of
molecular mass over a concentration range of 0.5-100 ,tM. The
analysis was performed in both H20 and 2H20 to permit
simultaneous determination of the partial specific volume (11,
12). The distribution of peptide (monitored at 230 nm) with
radius (Fig. 3C) fit closely, independent of the solvent, to that
predicted for a single species, as shown by the small residuals
obtained (Fig. 3A and B). Molecular mass at all concentrations
was determined as 3387 ± 334 Da and partial specific volume
as 0.715 ± 0.024 ml/g. The mass determined is close to that
predicted from the peptide sequence (3727 Da), with no
evidence for a dimer or higher-order structure. Similar results
were obtained from measurements in H20 at multiple rotor
speeds and temperatures (data not shown). In all cases, anal-
yses of the peptide distribution gave no evidence of species
larger than the monomer. Therefore, peptide A is monomeric
at concentrations where it exhibits a-helical character.
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FIG. 2. Analysis of peptide structure. CD spectra of peptides A, B,
D, and E. Double minima at 222 and =205 nm and a maximum at 192
nm are characteristic spectra of a-helices, while a weak maximum at
215 nm and an intense minimum at 195 nm are characteristic of
random coil (19). The mean residue ellipticities indicate helical con-
tents of 22%, 42%, 0%, and 25% (20) for peptides A, B, D, and E,
respectively, at 100 ,uM.
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FIG. 3. Equilibrium sedimentation data for peptide A in H20 and
2H20 (D20). (A and B) Residuals (theoretical for a single ideal species
- observed values at each data point) for the H20 and D20 data,
respectively. (C) Primary equilibrium sedimentation data.
Helicity of Shorter Peptides. One way that peptide A could
fold into a monomer with a-helical character would be for the
separate regions of predicted helix to interact. We therefore
synthesized peptides corresponding to separate regions of
peptide A (Fig. 1). CD spectra for peptides B and E, which
correspond to predicted helices I and II (Fig. 1), showed
substantial levels of a-helix at concentrations of 100 ,uM in
aqueous solution (Fig. 2). The intensities of the minima at 222
nm indicated helical contents of -42% and -25% for peptides
B and E, respectively. In contrast, peptide D, corresponding to
the glycine-rich region (Fig. 1), displayed a spectrum charac-
teristic of a random coil, with a weak maximum at 218 nm and
an intense minimum at 195 nm (Fig. 2). We next tested whether
the helicities of peptides B and E were concentration depen-
dent. The mean residue ellipticities at 222 nm decreased sub-
stantially with lower peptide concentrations, suggesting that
helicity depended on the formation of dimers or other higher-
order structures (data not shown). This was consistent with the
predicted amphipathic nature of the helices (6) but was in
contrast to the behavior of peptide A.
The 36-Residue Peptide Inhibits UL42-Mediated Long-
Chain DNA Synthesis. We hypothesized that peptides corre-
sponding to the C terminus of Pol could inhibit the Pol-UL42
interaction. We therefore tested the ability of peptide A to
inhibit UL42-dependent long-chain DNA synthesis, using a
modification of a previously reported assay (15, 16). In this
assay, a 32P-labeled primer on a homopolymeric template was
extended only a short distance by Pol alone (Fig. 4A, lane 3)
but was extended considerably further in the presence ofUL42
(lane 4; for control reactions without Pol, see lanes 1 and 2).
Increased chain length in the presence of UL42 reflects an
increase in the processivity of the enzyme (4, 5, 16) and
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FIG. 4. (A) Inhibition of HSV DNA polymerase by peptide A.
Polymerase assays using 32P-labeled oligo(dT) primers on a poly(dA)
template were carried out in the presence of the indicated concen-
tration (,uM) of peptide A. Pol was omitted from the reactions in lanes
1 and 2, and UL42 was added as indicated. Samples were electropho-
resed in an alkaline 4% agarose gel. Positions of DNA size markers
(bases) are indicated at left. The slight stimulation of long-chain
synthesis at 0.3 ,uM peptide A was not reproducible. (B) Peptide
dose-response curves. Long-chain DNA synthesis in the presence of
various amounts of each peptide was quantified. Values are expressed
as a fraction of the value obtained in the absence of peptide.
requires a stable interaction between the two subunits, as pol
and UL42 mutations that specifically impair the interaction
prevented the increase in chain length in this assay (data not
shown).
As hypothesized, peptide A inhibited long-chain synthesis
(Fig. 4A, compare lanes 4 and 14, for example), but had little
effect on the products synthesized by Pol alone (compare lanes
3 and 13). Importantly, in reaction mixtures containing UL42,
only long-chain synthesis was inhibited, and at peptide con-
centrations below 100 ,M, short-chain synthesis was unaf-
fected (compare lanes 4 and 16). This is consistent with the
proposed mechanism of the peptide specifically blocking the
Pol-UL42 association.
An 18-Residue Peptide Corresponding to Helix II Specifi-
cally Inhibits Long-Chain DNA Synthesis. We then derived
dose-response curves for the effects of each peptide on short-
chain (data not shown) and long-chain (Fig. 4B) DNA syn-
thesis, as a means of assessing the relative importance of the
different regions of the C terminus of Pol. Peptide A was the
most potent inhibitor of long-chain polymerization, with an
1458 Biochemistry: Digard'et aL
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IC50 of 2 ,uM, and showed considerable specificity, as 25-fold
more peptide was required to similarly inhibit DNA synthesis
by Pol alone (Fig. 4A). Of the shorter peptides, peptide E from
helix II (residues 1218-1235) was the most potent, inhibiting
UL42-dependent long-chain DNA synthesis with an IC50 value
of 30 ,uM (Fig. 4B). In contrast, its IC50 was >1500 ,AM for
short-chain synthesis catalyzed by Pol alone (data not shown).
Interestingly, peptide F, corresponding to most of helix II
except for three N-terminal residues (Fig. 1), was markedly less
potent than peptide E (Fig. 4B) but also had only about
one-fifth its helical content (data not shown). Peptides B-D,
corresponding to helix I and the loop region, and a variety of
other peptides ranging from 18 to 30 residues in length were
all much less potent than peptides A and E and showed little
or no evidence of specificity for UL42-mediated long-chain
synthesis compared with synthesis catalyzed by Pol alone (Fig.
4B and data not shown).
Specificity of Inhibition. The ratios of IC5o values for short-
and long-chain synthesis of peptides A and E (25:1 and >50:1,
respectively) and the lack of potency of other peptides argue
that peptides A and E specifically inhibit processive DNA
synthesis by the Pol-UL42 complex. As a further test of spec-
ificity, we examined the effects of these peptides on the anal-
ogous interaction between a cellular DNA polymerase, DNA
polymerase 8, and its processivity factor, PCNA (21, 22). As
expected, in the absence of PCNA, Pol 6 synthesized short
DNA products (Fig. 5, compare lanes 1 and 2). However,
neither short-chain nor PCNA-dependent long-chain synthesis
was inhibited by peptide E, at concentrations as high as 330 AM(Fig. 5). Similarly, peptide A at 100 ,uM showed no inhibition
of Pol &-PCNA DNA synthesis (data not shown). We conclude
that peptides A and E are specific inhibitors ofHSV Pol-UL42
long-chain DNA synthesis.
DISCUSSION
A Model for the Structure of the UL42 Binding Site of HSV
Pol. CD spectroscopy of peptides A, B, and E in aqueous
solution indicated that they contained substantial levels of
a-helix, consistent with earlier predictions of the structure of
the extreme C terminus of Pol (6). The degree of helicity of
peptides B and E, corresponding to predicted helices I and II,
respectively, depended on peptide concentration, suggesting
that the peptides self-associated. This was not unexpected,
given the predicted amphipathic nature of the helices (6) and
the observation that short monomeric a-helices are generally
_rp z ^E? t 8>4? MM Peptide E
PCNA: - + -±-+-+-+-+-±
FIG. 5. Titration of peptide E with Pol 8 and PCNA. Polymerase
assays were carried out in the presence of the indicated concentrations
of peptide, with PCNA included as shown. A longer exposure is shown
of the bottom portion of the gel to allow visualization of the short DNA
products synthesized by Pol 8 in the absence of PCNA. Nonspecific
stimulation of polymerase activity by high concentrations of nonin-
hibitory peptides was also often seen with HSV Pol (data not shown).
unstable in aqueous solution (23). In contrast, the helicity of
peptide A was apparently independent of peptide concentra-
tion, and equilibrium analytical centrifugation confirmed that
the peptide was monomeric in solution. Interestingly, the he-
lical content of peptideAwas similar to that expected from the
helical contents of peptides B and E at high concentrations.
One potential explanation for these findings is that the
increased length of peptide A may permit the formation of a
monomeric linear a-helix. We think this is unlikely because the
helix would still be amphipathic and expected to self-associate,
as did peptides B and E. Instead, we favor a structure for
peptide A in which intramolecular interactions, possibly in-
cluding helix-helix interactions, form a discrete hairpin-like
structure, permitting stabilization of short stretches of a-helix.
This model is supported by the monomeric nature of peptide
A and the propensity of peptides corresponding to the pre-
dicted individual helices to form higher-order structures. Pre-
liminary nuclear magnetic resonance spectroscopic investiga-
tions of peptide A are consistent with its helical content
detected by CD and with intramolecular interactions (Q. X.
Hua, P.D., C.E.D., D.M.C., and M. Weiss, unpublished re-
sults). Although we cannot exclude the possibility that the
C-terminal 36 residues of Pol fold into a different conforma-
tion in the intact protein, it would be surprising if the a-helical
character of the region were not preserved (24).
The observation that peptides A and E inhibited the func-
tional consequences of the Pol-UL42 interaction is most sim-
ply interpreted by the direct involvement of the corresponding
regions of Pol in UL42 binding. In confirmation of this, recent
evidence from plasmon surface resonance studies indicates
that peptide A can bind directly to UL42 (S. Mahdiyoun and
D.M.C., unpublished results). Overall, this is consistent with
mutational results that implicated the C-terminal 18-40 res-
idues as critical for UL42 binding (6, 8, 9, 25), although the
inhibitory effect of peptide E appears to argue against con-
clusions that residues downstream of aa 1216 are not important
(9, 26). The 10-fold lower potency of peptide E relative to
peptide A could be interpreted as indicating that UL42 makes
substantial contact with residues between aa 1200 and 1218
(the N-terminal boundaries of peptides A and E, respectively).
Alternatively, the helix II region may only be able to interact
meaningfully with UL42 when in an appropriate conforma-
tion, either when stabilized intramolecularly (e.g., when within
peptide A) or intermolecularly (e.g., by self-association of
peptide E). These possibilities can be addressed experimen-
tally; however, we note that the concentration of peptide E
required for substantial helical content (-20 ,uM; data not
shown) is similar to that required for inhibition of long-chain
synthesis (-30 ,uM; Fig. 4B). Recent work measuring the
relative affinities for UL42 of wild-type Pol and a mutant Pol
lacking the C-terminal 27 residues led to the conclusion that
the deleted region was required for 75% of the binding energy
(25). Nevertheless, although the C terminus of Pol is most
important for binding of UL42, upstream residues may still
play a role.
A Class of DNA Polymerase Inhibitors That Act by Blocking
Subunit Interactions. We have shown that peptides corre-
sponding to the C terminus of HSV Pol can inhibit long-chain
DNA synthesis mediated by Pol plus UL42 to a much greater
extent than polymerization mediated by Pol alone. In addition,
these peptides required much higher concentrations to inhibit
synthesis by cellular DNA Pol S. Thus, we conclude that
peptides A and E are specific inhibitors of HSV DNA poly-
merase that act by blocking UL42-dependent long-chain syn-
thesis. This would represent a class of polymerase inhibitors
whose mechanisms differ from those of most known inhibitors,
which act by binding to substrate- or product-binding sites. Our
results are consistent with the peptides acting as hypothesized
by blocking the protein-protein interaction between Pol and
UL42. In support of this is the preliminary finding that peptide
MP,-
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A can bind directly to UL42 (S. Mahdiyoun and D.M.C.,
unpublished results) and the work of Marsden et al. (25), who
recently found that a 27-residue peptide from the C terminus
of Pol blocked UL42-stimulated Pol activity and directly in-
hibited UL42 binding to Pol.
In contrast, UL42-derived peptides were found generally to
be nonspecific inhibitors of the Pol-UL42 complex (27). This
difference may reflect the UL42-binding site on Pol being
more conducive to peptide mimicry or may simply result from
the choices of peptides. Extensive mutagenesis of UL42 has
thus far failed to define a discrete region capable ofbinding Pol
(7, 15, 26), raising the possibility that unlike Pol, the major
interacting residues of UL42 may be noncontiguous.
Implications for Antiviral Drug Development. Genetic anal-
yses of the Pol-UL42 interaction in vitro and in the context of
the infected cell argue strongly that the interaction is essential
for HSV replication and thus represents a valid drug target.
Subunit interactions of HSV ribonucleotide reductase (28, 29)
and interactions of the HSV VP16 transactivating protein with
cellular proteins (30) have also been proposed as potential
targets for therapeutic intervention. However, unlike the Pol-
UL42 interaction, ribonucleotide reductase and VP16 trans-
activation are dispensable under certain circumstances (31,
32). Our results point to two routes to the rational design of
drugs against the Pol-UL42 interaction. The first route stems
from the biophysical data that indicate that the UL42-binding
site of Pol folds into a discrete structure. Preliminary results
suggest that a high-resolution structure of peptide A might be
tractable by nuclear magnetic resonance spectroscopy (Q. X.
Hua, P.D., C.E.D., D.M.C., and M. Weiss, unpublished re-
sults). With such a structure in hand, computer-aided design
of small molecules that bind specifically and inhibit the Pol-
UL42 interaction may be possible. Similar design efforts have
recently abetted the discovery of inhibitors of other antiviral
drug targets (e.g., refs. 33 and 34).
The second route to rational drug design stems from our
identification of peptides that specifically inhibit long-chain
DNA synthesis by HSV DNA polymerase. This suggests that
these peptides, or preferably shorter derivatives thereof, could
form the basis for the synthesis of peptidomimetics that could
inhibit HSV replication. Encouragement for this approach has
come from the synthesis of a drug based on a peptide corre-
sponding to the subunit interface of the HSV ribonucleotide
reductase. This drug is > 10,000-fold more potent for inhibition
of ribonucleotide reductase than the starting peptide and is
capable of exerting antiviral effects under conditions where the
reductase is required for HSV replication (38).
It is our hope that one or both of these routes will lead to
the discovery of clinically useful anti-HSV drugs and will
suggest similar strategies for inhibiting other dimeric herpes-
virus DNA polymerases (35-37).
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